Donald Trump’s sabre-rattling over China and his “America First” philosophy in terms of manufacturing could play into the hands of Hikma, a London-listed drugs giant.
Hikma, a constituent of the FTSE 100 index, specialises in branded generic drugs, many of which have become essential treatments for patients with Covid-19. Unlike some rivals, it has largely been unaffected this year by disruption in China when the country was at the epicentre of the pandemic.
Shares in Hikma have risen by just over 17% since the beginning of the year, but there are reasons to believe they should continue to perform. Hikma should be well placed to navigate the turbulent months ahead.
Founded in Jordan in 1978, Hikma has 8,600 staff in 50 countries. It made pre-tax